Wasatch Advisors Inc. increased its position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) by 43.6% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 2,610,818 shares of the biopharmaceutical company’s stock after purchasing an additional 793,306 shares during the period. Wasatch Advisors Inc. owned about 2.89% of Inovio Pharmaceuticals worth $20,469,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of INO. Wells Fargo & Company MN boosted its stake in Inovio Pharmaceuticals by 28.9% in the 1st quarter. Wells Fargo & Company MN now owns 124,565 shares of the biopharmaceutical company’s stock worth $825,000 after purchasing an additional 27,898 shares during the period. Bank of New York Mellon Corp boosted its stake in Inovio Pharmaceuticals by 3.6% in the 1st quarter. Bank of New York Mellon Corp now owns 342,348 shares of the biopharmaceutical company’s stock worth $2,266,000 after purchasing an additional 11,765 shares during the period. American International Group Inc. boosted its stake in Inovio Pharmaceuticals by 7.1% in the 1st quarter. American International Group Inc. now owns 40,856 shares of the biopharmaceutical company’s stock worth $270,000 after purchasing an additional 2,695 shares during the period. Teachers Advisors LLC boosted its stake in Inovio Pharmaceuticals by 2.3% in the 1st quarter. Teachers Advisors LLC now owns 151,775 shares of the biopharmaceutical company’s stock worth $1,005,000 after purchasing an additional 3,411 shares during the period. Finally, Vanguard Group Inc. boosted its stake in Inovio Pharmaceuticals by 7.9% in the 1st quarter. Vanguard Group Inc. now owns 3,098,055 shares of the biopharmaceutical company’s stock worth $20,510,000 after purchasing an additional 226,861 shares during the period. 24.83% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Inovio Pharmaceuticals, Inc. (INO) Position Boosted by Wasatch Advisors Inc.” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/inovio-pharmaceuticals-inc-ino-position-boosted-by-wasatch-advisors-inc/1632827.html.

A number of equities analysts recently commented on the stock. Citigroup Inc. assumed coverage on shares of Inovio Pharmaceuticals in a research note on Wednesday, September 6th. They issued a “buy” rating and a $10.00 price objective for the company. HC Wainwright set a $13.00 price objective on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, July 7th. ValuEngine raised shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, August 11th. BidaskClub lowered shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday. Finally, Aegis reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Inovio Pharmaceuticals in a research note on Tuesday, July 18th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company’s stock. Inovio Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $19.98.

Shares of Inovio Pharmaceuticals, Inc. (INO) traded down 1.42% during midday trading on Friday, hitting $6.24. 818,248 shares of the company’s stock were exchanged. Inovio Pharmaceuticals, Inc. has a 52 week low of $5.28 and a 52 week high of $9.86. The firm’s market cap is $563.02 million. The company has a 50-day moving average of $6.18 and a 200-day moving average of $6.65.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.08. The company had revenue of $20.41 million during the quarter, compared to analysts’ expectations of $16.29 million. Inovio Pharmaceuticals had a negative net margin of 153.46% and a negative return on equity of 63.67%. The business’s quarterly revenue was up 229.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.26) earnings per share. Equities research analysts expect that Inovio Pharmaceuticals, Inc. will post ($0.92) EPS for the current fiscal year.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Institutional Ownership by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.